Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

Intensive Care Medicine

Volumn 41, Issue 1, 2015, Pages 164-165

  Toffart, Anne Claire ^a,b   Dhalluin, Xavier ^c   Girard, Nicolas ^d,e   Chouaid, Christos ^f   Audigier Valette, Clarisse ^g   Duruisseaux, Michaël ^b,h   Mennecier, Bertrand ⁱ   Parrot, Antoine ^j   Fournel, Pierre ^k   Moro Sibilot, Denis ^a,b   Timsit, Jean François ^l,m  

^a UNIV GRENOBLE ALPES   (France)

^b HÔPITAL MICHALLON   (France)

^c Centre Hospitalier et Universitaire   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g Centre Hospitalier Intercommunal Toulon La Seyne sur Mer   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ HÔPITAL CIVIL   (France)

^j Hôpitaux Universitaires de l Est Parisien   (France)

^k INSTITUT DE CANCÉROLOGIE LUCIEN NEUWIRTH   (France)

^l BICHAT HOSPITAL   (France)

^m UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE RESPIRATORY FAILURE; ARTIFICIAL VENTILATION; CANCER MORTALITY; CANCER SURVIVAL; GENE MUTATION; HISTOLOGY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LETTER; NON SMALL CELL LUNG CANCER; NONINVASIVE VENTILATION; PLEURA EFFUSION; SURVIVAL RATE; SURVIVAL TIME; TRACHEOESOPHAGEAL FISTULA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; FRANCE; GENETICS; HOSPITAL ADMISSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; UTILIZATION;

EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TUMOR MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FRANCE; HUMANS; INTENSIVE CARE UNITS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PATIENT ADMISSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84918572467     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3535-x     Document Type: Letter

References (5)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
2. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394
3. Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K (2013) Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8:250–253
4. van Geffen WH, Hiltermann TJ, Groen HJ (2013) Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. J Thorac Oncol 8:e1–e2
5. Toffart AC, Minet C, Raynard B, Schwebel C, Hamidfar-Roy R, Diab S, Quetant S, Moro-Sibilot D, Azoulay E, Timsit JF (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108